Bill > S0886

This bill requires the Agency for Health Care Administration to conduct a study examining potential changes to drug pricing within Florida's Medicaid program, specifically focusing on the 340B Drug Pricing Program (a federal program that allows certain healthcare providers to purchase outpatient drugs at discounted rates). The study will explore several potential provisions, including requiring drug manufacturers to sell certain drugs to Medicaid pharmacies at 340B Program discounted prices, mandating that pharmacy benefits managers pay pharmacies the 340B discounted price plus a professional dispensing fee, and requiring drug wholesalers to sell drugs at 340B discounted prices for preferred drugs. The bill also proposes that if a drug's 340B discounted price is higher than the state's negotiated Medicaid price, the manufacturer must pay a rebate equal to the difference. Medicaid pharmacies would be required to offer these discounted drugs only to Medicaid recipients. The agency must complete the study and submit its results to the Governor, Senate President, and House Speaker by January 31, 2027, with the act taking effect on July 1, 2026. The goal appears to be exploring ways to potentially reduce drug costs within the Medicaid program by leveraging existing federal drug pricing mechanisms.

https://www.flsenate.gov/Session/Bill/2026/886